Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 August 2022 | Story Leonie Bolleurs | Photo Supplied
Marike Stander
For the first time in her life, Marike Stander accompanied a group of researchers for their annual relief expedition with the SA Agulhas II from Cape Town to Marion Island, where she assisted with fieldwork and data collection. Here she is pictured at the snow-covered Karookop.


The Prince Edward Islands are the most southerly part of South Africa’s official territory and consist of Marion Island and Prince Edward Island. On Marion Island, about 270 km² in size and situated in the sub-Antarctic Indian Ocean, 1 920 km from the South African shore, activities are restricted to research and conservation management. 

This is where Marike Stander, Lecturer in the Department of Geography at the University of the Free State (UFS), was granted the opportunity to assist a research group led by Prof Werner Nel (University of Fort Hare) and Prof David Hedding (Unisa) – based on her knowledge and experience in tracer sampling. 

Back home, Stander is working to complete her doctoral research, investigating the often-overlooked major issue of soil erosion. She believes the management of soil erosion, a global issue, is key. According to her, it impacts the storage of carbon and nutrients, and therefore the production of food, but it can also act as a pollutant in water sources.

Fieldwork and data collection

She was approached by the Sub-Antarctic Landscape-Climate Interactions (SANAP-LCI) Research Group, a project funded by the South African National Antarctic Programme-NRF. One of their research objectives is to explore the viability of using geochemical tracers in the substrate on Marion Island, the focus of Stander’s doctoral research. 

With the support of the UFS Faculty of Natural and Agricultural Sciences and the Department of Geography, she was released to accompany the research group for the first time in her life on their annual relief expedition with the SA Agulhas II from Cape Town to Marion Island, where she assisted with fieldwork and data collection. During this three-week field campaign, Stander collected sediment samples for the tracer project, as well as rock and peat samples.

With the SANAP-LCI group collaborating with research labs in the United Kingdom and France, she was able to bring her expertise to the table, while at the same time learning about other geochronological techniques and field methods.  

She was also excited about the exposure to the work of a myriad of researchers in various fields from around the world. Stander says in a time when the importance of interdisciplinary and multidisciplinary work is being emphasised, it was invaluable to meet and learn from various distinguished scientists.  “It changes your perspective and allows your mind to not only think outside the box, but also to think about all the interconnected boxes and how they affect each other.”

She believes being exposed to various sampling strategies from different scientists also broaden one’s skill set and experience. “Using your capabilities and skills in a different setting builds depth to your skill set and expands your horizon.”

Volcanoes and albatrosses 

Very few people get the opportunity to visit Marion Island. Thus, just the chance to visit and experience life on the island is described by many as one of their most memorable events. Always fascinated by volcanic features, Stander was completely captivated by this relatively young volcanic island. “There are so many interesting features, such as the pahoehoe and a’a lava flows, as well as the numerous scoria cones,” describes Stander, who cannot believe that she managed to cover the vast distances in gumboots, the only footwear that are effective to cross anything – from razor-sharp rocks to deep waterlogged mires.

She was also overwhelmed by the flora and fauna on the island.  “It is so very different from what we are used to and from what I’ve experienced before.  Seeing these animals in a relatively untouched remote location really captivated me,” she says. 

“More specifically, I fell in love with the albatrosses.  These remarkable seabirds cover vast distances over the ocean looking for food. They are unfortunately threatened by the invasive mice on Marion Island.” Stander invites people to help organisations such as Mouse-Free Marion to take on the difficult task of eradicating these mice. Find them at www.mousefreemarion.org.

On a lighter note, Stander also learnt a thing or two that was totally new to her. For instance, that there are radio telescopes installed on the radio-quiet Marion Island, searching for the universe’s first stars. And that male elephant seals that drive out all other male competitors during mating season are called ‘beachmasters’. She learned that these ‘beachmaster’ bulls have a harem of female elephant seals and can weight up to three tons.


• She wishes to thank Prof Werner Nel, Prof David Hedding, and Dr Liezel Rudolph (UFS) from the SANAP-LCI project for affording her the opportunity to join the expedition. She also thanks the SANAP-NRF and the Department of Forestry, Fisheries, and the Environment for making the expedition possible. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept